What are the characteristics of PHARMING GROUP stock?

PHARMING GROUP is a company operating in the Biotechnologies sector. The stock is listed on Euronext Amsterdam under ISIN NL0010391025.

What is the recent price evolution of PHARMING GROUP stock?

Since last close: -2.39 %. Over one week: -7.03 %. Over one year: -25.16 %.

Pharming Group to Participate in the Jefferies Global Healthcare Conference in New York

CEO Fabrice Chouraqui will engage in a Fireside Chat session on Thursday, June 4.

Published on Jun 02, 2026 at 10:09

PHARMING GROUP

0.91 € -2.39 %

Add us as a preferred source on Google

A presentation for investors and sector analysts

Pharming Group is participating in the Jefferies Global Healthcare Conference held in New York on June 3 and 4, 2026. Fabrice Chouraqui, CEO of the group, will take part in a question-and-answer session (Fireside Chat) on Thursday, June 4 at 11:05 AM Eastern Time / 5:05 PM Paris Time. This participation is part of Pharming's regular interactions with investors and health sector analysts. The presentation will be broadcast live, and a replay will be available in the 'Events and Presentations' and 'News' sections of Pharming's website.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Santé

🗞️ Sanofi shares lose ground and fall back to their lowest level in a year 🗞️ Abivax stock declines but retains nearly 38% gain over one year 🗞️ Medincell stock plunges 22% in three months and breaks through its support levels 🗞️ MaaT Pharma: Negative CHMP Voting Trend on MaaT013 (Xervyteg)

Context

Period

Period: S1 2026

Key reported figures

Revenue: 162,7 millions de dollars
Quarterly revenue: 162,7 millions de dollars
Revenue growth: -6 %
EBITDA: 2,4 millions de dollars
Net income: -3,6 millions de dollars

Risks mentioned

Baisse de 12 % des revenus RUCONEST sur le semestre, tirée par les volumes
Perte opérationnelle de 3,6 M$ contre un profit de 3,8 M$ un an plus tôt
Dépréciations de stocks portées à 16,6 M$ au bilan au 30 juin 2026

Opportunities identified

Progression de 37 % des revenus Joenja au premier semestre 2026
Autorisation de mise sur le marché européenne de Joenja obtenue le 22 mai 2026
Amélioration de 15 M$ de la prévision de charges opérationnelles 2026

Outlook / guidance

Expected revenue: 375 millions de dollars
Management commentary: Total revenues between US$375.0 million and US$395.0 million (0% to 5% growth), updated to reflect a US$30 million reduction compared with prior guidance.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

A presentation for investors and sector analysts

Context

Also read